{"id":"NCT01435018","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","briefTitle":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","officialTitle":"A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-01","primaryCompletion":"2018-03-13","completion":"2019-08-29","firstPosted":"2011-09-15","resultsPosted":"2019-04-08","lastUpdate":"2021-10-20"},"enrollment":334,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"Etoposide (ET)","otherNames":[]},{"type":"DRUG","name":"Bleomycin and Vincristine (BV)","otherNames":[]},{"type":"DRUG","name":"Paclitaxel (PTX)","otherNames":[]},{"type":"DRUG","name":"Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)","otherNames":[]}],"arms":[{"label":"ET+ART","type":"EXPERIMENTAL"},{"label":"BV+ART","type":"EXPERIMENTAL"},{"label":"PTX+ART","type":"ACTIVE_COMPARATOR"}],"summary":"This study was done to compare the safety and efficacy of three combination treatments for Kaposi's Sarcoma (KS) and AIDS:\n\n1. Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) (ET+ART),\n2. Bleomycin and Vincristine (BV) plus co-formulated EFV/FTC/TDF (BV+ART),\n3. Paclitaxel (PTX) plus co-formulated EFV/FTC/TDF (PTX+ART).","primaryOutcome":{"measure":"Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART","timeFrame":"From study entry to week 48","effectByArm":[{"arm":"ET+ART","deltaMin":19.7,"sd":null},{"arm":"PTX+ART","deltaMin":49.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Brazil","Kenya","Malawi","South Africa","Uganda","Zimbabwe"]},"refs":{"pmids":["2671281","11773164","32145827"],"seeAlso":["http://rsc.tech-res.com/docs/default-source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8","http://rsc.tech-res.com/docs/default-source/safety/manual_for_expedited_reporting_aes_to_daids_v2.pdf?sfvrsn=12"]},"adverseEventsSummary":{"seriousAny":{"events":54,"n":132},"commonTop":["Blood albumin decreased","Blood sodium decreased","Neutrophil count decreased","Haemoglobin decreased","Aspartate aminotransferase increased"]}}